The development of genomic tests and how validation affects their use in the clinic - European Medical Journal

The development of genomic tests and how validation affects their use in the clinic

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies.

This content is supported by Genomic Health, Inc.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>